BridgeMD
An Open-Label Phase 2 study to evaluate the effect of PT2977 for the treatment of von Hippel-Lindau Disease-Associated with kidney cancer
EU CTIS ID: 2023-509119-99-00
What this study is testing
To evaluate the efficacy of PT2977 (belzutifan) for the treatment of von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) as measured by overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by an independent review committee (IRC).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Has the ability to understand and willingness to provide documented informed consent form before the performance of any study-specific procedures
- 2. 18 years of age or older
- 3. Has a diagnosis of von Hippel-Lindau disease, based on a germline VHL alteration
- 4. Has at least 1 measurable solid RCC tumor and no RCC tumor greater than 3.0 cm that requires immediate surgical intervention. The diagnosis of RCC can be radiologic (histologic diagnosis not required). Patients may have VHL disease-associated tumors in other organ systems
- 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- 6. Has organ and marrow function as defined in the protocol.
You likely can't join if
- 1. Has participated in another clinical trial of an investigational drug (or a medical device) within 30 days of study enrollment
- 10. Has hypersensitivity to the active pharmaceutical ingredient or any component in the Formulation
- 11. Has an active infection requiring systemic treatment.
- 12. Has had any major cardiovascular event within 6 months prior to study drug administration including but not limited to myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic event, pulmonary embolism, clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or New York Heart Association Class III or IV heart failure.
- 13. Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results, in the opinion of the investigator or medical monitor.
- 14. If a female patient, intends to breast feed a child while on study drug or within 30 days after administration of the last dose of study drug.
See the full eligibility criteria
Who can join
- 1. Has the ability to understand and willingness to provide documented informed consent form before the performance of any study-specific procedures
- 2. 18 years of age or older
- 3. Has a diagnosis of von Hippel-Lindau disease, based on a germline VHL alteration
- 4. Has at least 1 measurable solid RCC tumor and no RCC tumor greater than 3.0 cm that requires immediate surgical intervention. The diagnosis of RCC can be radiologic (histologic diagnosis not required). Patients may have VHL disease-associated tumors in other organ systems
- 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- 6. Has organ and marrow function as defined in the protocol.
- 7. Male patients are eligible to participate if they agree to the following during the intervention period and for at least 7 days after the last dose of study intervention: A) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent; OR B) Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause as detailed below: - Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration. C) Male patients must also agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person of any sex. D) Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- 8. A female patient is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a WOCBP; OR A) Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a longterm and persistent basis), as described in Appendix 2 during the intervention period and for at least 30 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. B) A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention. C) If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the patients must be excluded from participation if the serum pregnancy result is positive. D) Additional requirements for pregnancy testing during and after study intervention are located in Appendix 2. E) The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. F) Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- 9. Able to swallow oral medications and comply with study procedures
What rules you out
- 1. Has participated in another clinical trial of an investigational drug (or a medical device) within 30 days of study enrollment
- 10. Has hypersensitivity to the active pharmaceutical ingredient or any component in the Formulation
- 11. Has an active infection requiring systemic treatment.
- 12. Has had any major cardiovascular event within 6 months prior to study drug administration including but not limited to myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic event, pulmonary embolism, clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or New York Heart Association Class III or IV heart failure.
- 13. Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results, in the opinion of the investigator or medical monitor.
- 14. If a female patient, intends to breast feed a child while on study drug or within 30 days after administration of the last dose of study drug.
- 15. A WOCBP who has a positive urine pregnancy test within 24 hours prior to the first dose of study intervention (see Appendix 2). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- 16. Adults without legal capacity, under guardianship or curatorship, deprived of their liberty.
- 2. Has received prior treatment with belzutifan or another HIF-2α inhibitor
- 3. Has had any systemic anti-cancer therapy (includes anti-VEGF therapy or any systemic investigational anti-cancer agent).
- 4. Has had radiotherapy within 4 weeks prior to study enrollment.
- 5. Has had surgical procedure for VHL disease or any major surgical procedure completed within 4 weeks prior to study enrollment.
- 6. Has an immediate need for surgical intervention for tumor treatment.
- 7. Has a prior or concomitant non-VHL disease-associated invasive malignancy with the exception of adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma in situ or any other malignancy from which the patient has remained disease free for more than 2 years.
- 8. Evidence of metastatic disease on screening imaging.
- 9. Has malabsorption due to prior gastrointestinal (GI) surgery or GI disease.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.